Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-267 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose (SAD) | PLACEBO_COMPARATOR | Healthy volunteers, receiving single ascending doses of ABT-267 or placebo. |
| Multiple Ascending Dose (MAD) | PLACEBO_COMPARATOR | Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor. |
| Food Effect (FE) | ACTIVE_COMPARATOR | Healthy volunteers, receiving ABT-267, multi-dose, food effect. |
| Antiviral Activity | PLACEBO_COMPARATOR | HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days. |
| Resistance Monitoring | NO_INTERVENTION | HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the "Antiviral Activity" arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected |
| Name | Type | Description |
|---|---|---|
| ABT-267 | DRUG | See arm description |
| Placebo | DRUG | See arms description |
| Blood Sample Collection | PROCEDURE | See arm description |
| Cytochrome P450 inhibitor | DRUG | See arm description |
Inclusion Criteria Main Selection Criteria for Healthy Volunteers: * Subject has provided written consent. * Subject is in general good health. * Females must be post-menopausal for at least 2 years or surgically sterile. * Females must not be pregnant or breast-feeding. If male, subject is surgic...
Top 20 of 28 competitors
ABT-267 is an investigational small molecule being developed for the treatment of HCV Infection, specifically hepatitis C virus genotype 1 infection. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ABT-267 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is in Phase 1 clinical development for the treatment of HCV Infection.
ABT-267 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of HCV Infection.
ABT-267 has been studied in one completed Phase 1 clinical trial, NCT01181427, which enrolled 137 participants. The trial was a randomized, double-blind, placebo-controlled study conducted in the United States, evaluating the drug in healthy volunteers and subjects with hepatitis C virus genotype 1 infection.
ABT-267 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of HCV Infection. The drug has completed one Phase 1 trial, but it remains under clinical investigation and has not received marketing approval.
ABT-267 is a small molecule being developed for the treatment of HCV Infection. The specific molecular target of ABT-267 has not been disclosed in available information, so its exact mechanism of action is not publicly detailed.